1. Sophie Laroche (WHO)
  2. Global initiatives
  3. Tuesday, 28 April 2015

Dear Tech Net Colleagues,

The Pandemic Influenza Preparedness (PIP) Framework promotes the development of systems and information specific to responding to public health influenza emergencies. Based on lessons learned from the WHO H1N1 response and other gap analyses, a series of objectives have been identified that cut across technical areas of WHO. One of the four overarching objectives of the PIP is to ensure that deployment and regulatory systems are developed as a common approach that would ultimately be used by all agencies responding to an influenza pandemic, including UN agencies, industry, civil society, financial support mechanisms and country governments.

A simulation tool to support planning and allocations of influenza vaccines during a pandemic has been developed and a prototype will be presented at the Innovations Café, during the Tech Net in Bangkok. The idea of the tool is to be able to run a simulation once per year in order to improve stakeholder response for the deployment of influenza vaccines during a pandemic.

The WHO team involved in the development of that tool will be present at the Innovation Café and would welcome your feedback on it. The tool, called “PIPDEPLOY”, has an interface dedicated to each stakeholder.

This is a unique opportunity to test the tool and provide comments in order to improve your interface dashboard. This will therefore contribute to the development of the final version.

We invite you to interact with us at any time during the week. Longer sessions could also be arranged to provide further information on the functionality of the tool.

This is a unified approach to enable better response to pandemics and to improve WHO support to countries. Your feedback is valuable to us!

Chers collègues Tech Net -21,

Dans le cadre du programme PIP, l’OMS est en train de développer un outil de planification pour l’allocation et ledéploiement des vaccins de la grippe en cas de pandémie. Un tel outil a été une des recommandations faites par les partenaires après la pandémie de 2009-2010. Cet outil prioritairement développé dans le but de préparer les pays à répondre à ce type d’urgence afin que la réponse globale soit coordonnée. L’OMS envisage de lancer une simulation par année pour tenir les pays en alerte et identifier les failles dans le système. La première simulation devait avoir lieu en fin d’année 2015.

L’outil comprend trois interfaces, les industriels pharmaceutiques (fabricants de vaccins), l’OMS et les pays éligibles qui recevront les vaccins.

Un prototype a été développé que nous avons présenté à Genève au siège de l’OMS le 16 avril 2015 au "Pandemic Influenza Preparedness Advisory Groupmeeting"afin de revoir les commentairesprincipalement des industriels pharmaceutiques présents.

Nous aimerions saisir l’opportunité, au TechNet-21 Meeting de Bangkok, de recevoir les commentaires des pays et partenaires présents. Nous présenterons le prototype dans le cadre du café des innovations et nous pourrons également organiser des démonstrations plus poussées par petits groupes.

Votre feedback sur cet outil est primordial pour développer une version le plus aboutie possible et qui intègre les réels besoins des pays.

En espérant vous rencontrez et pouvoir échanger sur le sujet avec vous,

N’hésitez pas à nous contacter à l’avance si vous désirez de plus amples renseignements sur le projet ou fixer un rendez-vous durant le meeting !

WHO team

HEDMAN, Ms Lisa, technical officer, WHO HQ/PAU Policy, Access and Use ([email protected])

PIEVAROLI, Ms Liliana Marcela, Project manager WHO HQ/BSS Business Solution Services

LAROCHE, Ms Sophie, technical Officer, WHO HQ/PAU Policy, Access and Use ([email protected])

Attachments (1)
Accepted Answer Pending Moderation


"H1N1 Newer Vaccine Usage: Experiences from Karnataka State"was published inIndian J Community Med. 2012 Apr-Jun; 37(2): 134–136. I wish to share the ppt on the same presented in the "Karnataka Association of Community Health" 2010 held on 22/23 Oct 2010. Very high utilization rate and very low vaccine wastage were attributable to the meticulous microplan developed by the author in accordance with the National and WHO guidelines. More details (microplan/recording/reporting/monitoring/ formats/feedback template etc) can be exchanged at the conference. Exclusion criteria at the session site was the new indicator added in this study.

Hope may be useful.

Attachments (1)
  1. more than a month ago
  2. Global initiatives
  3. # 1
Accepted Answer Pending Moderation

With pleasure, we could also discuss it during the meeting ? Cheers,


  1. more than a month ago
  2. Global initiatives
  3. # 2
Accepted Answer Pending Moderation

I am not very clear whether developing a template of microplan for mass vacination for introducing a newer vaccine not routinely used in the National Immunization Schedule but will be administered in the highrisk community/population when needed and the operational guidelines will help/meet the requirement. If these two are helpful, I can share what I developed in March 2010.

  1. more than a month ago
  2. Global initiatives
  3. # 3
  • 1

There are no replies made for this post yet.
Be one of the first to reply to this post!